Literature DB >> 15194314

Can the use of marginal liver donors change recipient survival rate?

M B Rocha1, I F S F Boin, C A F Escanhoela, L S Leonardi.   

Abstract

Liver transplantation as a therapeutic method for the treatment of end-stage liver disease is beclouded by a scarcity of organs. The aim of this study was to retrospectively analyze the relation between the classification of donors as marginal versus ideal and recipients survival after 148 of 197 orthotopic liver transplantations (OLT) performed from 1991 to 2001. Donors were classified as marginal if they showed the major criteria of: age over 55 years, aspartate aminotransferase greater than 150 UI/L; serum bilirubin greater than 2 mg/dL, serum sodium greater 150 mEq/L, high-dose dopamine or any other vasoactive amine, cardiac arrest, intensive care unit (ICU) stay over 5 days, and moderate severe macrosteatosis. The minor criteria for a marginal donor were: use of dopamine below 10 microg/kg/min, history of alcoholism, drug abuse, ICU stays less than 4 days, microsteatosis of any degree, and mild macrosteatosis. Statistical analysis was performed using Cox regression analyzing and the Kaplan-Meier survival method. The rate of marginal donors was 61.5%. The 180 postoperative day survival was 77.0%. Survival rates were 81.1% for recipients of marginal donor organs, and 70.7% for ideal donor recipients (P >.05). In conclusion, the use of marginal liver donors is viable and safely expands the numbers of liver transplants, thereby diminishing the number of waiting list deaths.

Entities:  

Mesh:

Year:  2004        PMID: 15194314     DOI: 10.1016/j.transproceed.2004.03.116

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Application of the BAR score as a predictor of short- and long-term survival in liver transplantation patients.

Authors:  Ivan Dias de Campos Junior; Raquel Silveira Bello Stucchi; Elisabete Yoko Udo; Ilka de Fátima Santana Ferreira Boin
Journal:  Hepatol Int       Date:  2014-08-09       Impact factor: 6.047

2.  BAR, SOFT AND DRI POST-HEPATIC TRANSPLANTATION: WHAT IS THE BEST FOR SURVIVAL ANALYSIS?

Authors:  Fernando Torterolli; Rafael Katsunori Watanabe; Fernando Issamu Tabushi; Igor Luna Peixoto; Paulo Afonso Nunes Nassif; Nertan Luiz Tefilli; Sergio Luiz Rocha; Osvaldo Malafaia
Journal:  Arq Bras Cir Dig       Date:  2021-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.